Dianthus Therapeutics (DNTH) Projected to Announce Quarterly Earnings on Thursday

Dianthus Therapeutics (NASDAQ:DNTH) is expected to be announcing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Dianthus Therapeutics to post earnings of ($0.8463) per share and revenue of $0.2970 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:00 PM ET.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. On average, analysts expect Dianthus Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Dianthus Therapeutics Stock Performance

Shares of DNTH stock opened at $106.02 on Tuesday. Dianthus Therapeutics has a 52-week low of $18.08 and a 52-week high of $114.55. The stock has a market cap of $5.80 billion, a price-to-earnings ratio of -25.67 and a beta of 1.22. The firm has a fifty day moving average of $93.02 and a 200-day moving average of $79.05.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on DNTH. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Wedbush lifted their price objective on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Finally, Raymond James Financial reiterated a “strong-buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $117.82.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $362,480. This trade represents a 86.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Ryan Savitz sold 31,249 shares of the company’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the sale, the executive vice president directly owned 31,249 shares in the company, valued at approximately $3,157,086.47. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 87,779 shares of company stock valued at $7,985,235. 3.02% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its position in Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after acquiring an additional 2,503,311 shares during the last quarter. Vestal Point Capital LP raised its position in Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. State Street Corp raised its position in Dianthus Therapeutics by 124.7% in the 4th quarter. State Street Corp now owns 1,507,619 shares of the company’s stock valued at $62,129,000 after purchasing an additional 836,571 shares during the last quarter. Polar Capital Holdings Plc acquired a new position in Dianthus Therapeutics in the third quarter worth $29,434,000. Finally, Marshall Wace LLP acquired a new stake in shares of Dianthus Therapeutics in the third quarter valued at $22,545,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.